137 related articles for article (PubMed ID: 15179440)
1. Prevention of heterotopic ossification after spinal cord injury with COX-2 selective inhibitor (rofecoxib).
Banovac K; Williams JM; Patrick LD; Levi A
Spinal Cord; 2004 Dec; 42(12):707-10. PubMed ID: 15179440
[TBL] [Abstract][Full Text] [Related]
2. Similar effects of rofecoxib and indomethacin on the incidence of heterotopic ossification after hip arthroplasty.
van der Heide HJ; Rijnberg WJ; Van Sorge A; Van Kampen A; Schreurs BW
Acta Orthop; 2007 Feb; 78(1):90-4. PubMed ID: 17453398
[TBL] [Abstract][Full Text] [Related]
3. Selective COX-2 inhibitor versus indomethacin for the prevention of heterotopic ossification after hip replacement: a double-blind randomized trial of 100 patients with 1-year follow-up.
Grohs JG; Schmidt M; Wanivenhaus A
Acta Orthop; 2007 Feb; 78(1):95-8. PubMed ID: 17453399
[TBL] [Abstract][Full Text] [Related]
4. Rofecoxib inhibits heterotopic ossification after total hip arthroplasty.
van der Heide HJ; Koorevaar RC; Lemmens JA; van Kampen A; Schreurs BW
Arch Orthop Trauma Surg; 2007 Sep; 127(7):557-61. PubMed ID: 17106714
[TBL] [Abstract][Full Text] [Related]
5. Analgesic efficacy of the cyclooxygenase-inhibiting nitric oxide donor AZD3582 in postoperative dental pain: Comparison with naproxen and rofecoxib in two randomized, double-blind, placebo-controlled studies.
Michael Hill C; Sindet-Pederson S; Seymour RA; Hawkesford JE; Coulthard P; Lamey PJ; Gerry Cowan C; Wickens M; Jeppsson L; Dean AD; Svensson O
Clin Ther; 2006 Sep; 28(9):1279-95. PubMed ID: 17062301
[TBL] [Abstract][Full Text] [Related]
6. Effects of perioperative administration of a selective cyclooxygenase 2 inhibitor on pain management and recovery of function after knee replacement: a randomized controlled trial.
Buvanendran A; Kroin JS; Tuman KJ; Lubenow TR; Elmofty D; Moric M; Rosenberg AG
JAMA; 2003 Nov; 290(18):2411-8. PubMed ID: 14612477
[TBL] [Abstract][Full Text] [Related]
7. TOCOX--a randomised, double-blind, placebo-controlled trial of rofecoxib (a COX-2-specific prostaglandin inhibitor) for the prevention of preterm delivery in women at high risk.
Groom KM; Shennan AH; Jones BA; Seed P; Bennett PR
BJOG; 2005 Jun; 112(6):725-30. PubMed ID: 15924527
[TBL] [Abstract][Full Text] [Related]
8. The VIOXX in Prostate Cancer Prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups.
van Adelsberg J; Gann P; Ko AT; Damber JE; Logothetis C; Marberger M; Schmitz-Drager BJ; Tubaro A; Harms CJ; Roehrborn C
Curr Med Res Opin; 2007 Sep; 23(9):2063-70. PubMed ID: 17651539
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of rofecoxib in patients with chronic low back pain: results from two 4-week, randomized, placebo-controlled, parallel-group, double-blind trials.
Katz N; Ju WD; Krupa DA; Sperling RS; Bozalis Rodgers D; Gertz BJ; Gimbel J; Coleman S; Fisher C; Nabizadeh S; Borenstein D;
Spine (Phila Pa 1976); 2003 May; 28(9):851-8; discussion 859. PubMed ID: 12941996
[TBL] [Abstract][Full Text] [Related]
10. Heterotopic ossification mimicking infection in patients with traumatic spinal cord injury.
Citak M; Grasmücke D; Salber J; Cruciger O; Meindl R; Schildhauer TA; Aach M
Technol Health Care; 2016; 24(1):87-91. PubMed ID: 26409557
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment.
Thal LJ; Ferris SH; Kirby L; Block GA; Lines CR; Yuen E; Assaid C; Nessly ML; Norman BA; Baranak CC; Reines SA;
Neuropsychopharmacology; 2005 Jun; 30(6):1204-15. PubMed ID: 15742005
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
Bresalier RS; Sandler RS; Quan H; Bolognese JA; Oxenius B; Horgan K; Lines C; Riddell R; Morton D; Lanas A; Konstam MA; Baron JA;
N Engl J Med; 2005 Mar; 352(11):1092-102. PubMed ID: 15713943
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies.
Schnitzer TJ; Weaver AL; Polis AB; Petruschke RA; Geba GP;
J Rheumatol; 2005 Jun; 32(6):1093-105. PubMed ID: 15940774
[TBL] [Abstract][Full Text] [Related]
14. [Selective COX-2 inhibitor versus nonselective COX-1 and COX-2 inhibitor in the prevention of heterotopic ossification after total hip arthroplasty: a meta-analysis of randomised trials].
Xu BG; Xue DT; Wang XH; Yan SG
Zhongguo Gu Shang; 2014 Jul; 27(7):609-14. PubMed ID: 25338452
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients.
Higuchi T; Iwama T; Yoshinaga K; Toyooka M; Taketo MM; Sugihara K
Clin Cancer Res; 2003 Oct; 9(13):4756-60. PubMed ID: 14581346
[TBL] [Abstract][Full Text] [Related]
16. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group.
Ehrich EW; Schnitzer TJ; McIlwain H; Levy R; Wolfe F; Weisman M; Zeng Q; Morrison B; Bolognese J; Seidenberg B; Gertz BJ
J Rheumatol; 1999 Nov; 26(11):2438-47. PubMed ID: 10555907
[TBL] [Abstract][Full Text] [Related]
17. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
Sowers JR; White WB; Pitt B; Whelton A; Simon LS; Winer N; Kivitz A; van Ingen H; Brabant T; Fort JG;
Arch Intern Med; 2005 Jan; 165(2):161-8. PubMed ID: 15668361
[TBL] [Abstract][Full Text] [Related]
18. Development of heterotopic ossifications, blood markers and outcome after radiation therapy in spinal cord injured patients.
Krauss H; Maier D; Bühren V; Högel F
Spinal Cord; 2015 May; 53(5):345-8. PubMed ID: 25420497
[TBL] [Abstract][Full Text] [Related]
19. The effect of etidronate on late development of heterotopic ossification after spinal cord injury.
Banovac K
J Spinal Cord Med; 2000; 23(1):40-4. PubMed ID: 10752873
[TBL] [Abstract][Full Text] [Related]
20. Rofecoxib administration to paediatric patients undergoing adenotonsillectomy.
Sheeran PW; Rose JB; Fazi LM; Chiavacci R; McCormick L
Paediatr Anaesth; 2004 Jul; 14(7):579-83. PubMed ID: 15200656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
